Alvaro A Ordonez, Falk Saupe, Christoph A Kasper, Mitchell L Turner, Sadiya Parveen, Kelly Flavahan, Hyunsoo Shin, Dmitri Artemov, Simon J Ittig, Sanjay K Jain
BACKGROUND: Microbial-based cancer treatments are an emerging field, with multiple bacterial species evaluated in animal models and some advancing to clinical trials. Noninvasive bacteria-specific imaging approaches can potentially support the development and clinical translation of bacteria-based cancer treatments by assessing the tumor and off-target bacterial colonization. METHODS: 18F-Fluorodeoxysorbitol (18F-FDS) positron emission tomography (PET), a bacteria-specific imaging approach, was used to visualize an attenuated strain of Yersinia enterocolitica, currently in clinical trials as a microbial-based cancer treatment, in murine models of breast cancer...
October 3, 2023: Journal of Infectious Diseases
Shanshan Qin, Yuanyou Yang, Jiajia Zhang, Yuzhen Yin, Weihao Liu, Han Zhang, Xin Fan, Mengdie Yang, Fei Yu
Small cell lung cancer (SCLC) is a neuroendocrine tumor with a high degree of malignancy. Due to limited treatment options, patients with SCLC have a poor prognosis. We have found, however, that intravenously administered octreotide (Oct) armed with astatine-211 ([211 At]SAB-Oct) is effective against a somatostatin receptor 2 (SSTR2)-positive SCLC tumor in SCLC tumor-bearing BALB/c nude mice. In biodistribution analysis, [211 At]SAB-Oct achieved the highest concentration in the SCLC tumors up to 3 h after injection as time proceeded...
October 3, 2023: Molecular Pharmaceutics
Lisanne P Zijlker, Sonja Levy, Wendy Wolters, Johannes V van Thienen, Alexander C J van Akkooi, Margot E T Tesselaar
BACKGROUND: Immune checkpoint inhibitor treatment of patients with metastatic Merkel cell carcinoma (mMCC) has shown high response rates, ranging from 33% to 73%. The ideal duration of treatment, however, is currently unknown. The aim of this study was to evaluate if avelumab treatment for mMCC can be safely stopped after 1 year of treatment and a complete response (CR) confirmed by fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging. METHODS: Patients who received more than one dose of avelumab treatment for mMCC between November 2017 and February 2022 were included in this study...
October 3, 2023: Cancer
Ramez Philips, Angela Alnemri, Dev Amin, Jena Patel, Michael C Topf, Jennifer M Johnson, Voichita BarAd, Rita Axelrod, Athanassios Argiris, Christopher Fundakowski, Adam J Luginbuhl, David M Cognetti, Joseph M Curry
BACKGROUND: There is sparse literature on the effect of preoperative immunotherapy on complications after surgery for primary head and neck squamous cell carcinoma (HNSCC). The objectives are to compare complication rates in patients receiving surgery with and without neoadjuvant immune checkpoint inhibitors (nICI) for primary HNSCC and to evaluate factors associated with increased odds of surgical complications. METHODS: A retrospective review of patients who underwent ablation and free flap reconstruction or transoral robotic surgery (TORS) for primary HNSCC between 2017-2021 was conducted...
October 3, 2023: Cancer
Chirag H Patel, Yi Dong, Navid Koleini, Xiaoxu Wang, Brittany L Dunkerly-Eyring, Jiayu Wen, Mark J Ranek, Laura M Bartle, Daniel B Henderson, Jason G Sagert, David A Kass, Jonathan D Powell
MTORC1 integrates signaling from the immune microenvironment to regulate T cell activation, differentiation, and function. TSC2 in the tuberous sclerosis complex tightly regulates mTORC1 activation. CD8+ T cells lacking TSC2 have constitutively enhanced mTORC1 activity and generate robust effector T cells; however sustained mTORC1 activation prevents generation of long-lived memory CD8+ T cells. Here we show manipulating TSC2 at Ser1365 potently regulates activated but not basal mTORC1 signaling in CD8+ T cells...
October 3, 2023: JCI Insight
Marco Rubatto, Silvia Borriello, Nadia Sciamarrelli, Valentina Pala, Luca Tonella, Simone Ribero, Pietro Quaglino
Melanoma is a rare but highly lethal type of skin cancer whose incidence is increasing globally. Melanoma is characterized by high resistance to therapy and relapse. Despite significant advances in the treatment of metastatic melanoma, many patients experience progression due to resistance mechanisms. Epigenetic changes, including alterations in chromatin remodeling, DNA methylation, histone modifications, and non-coding RNA rearrangements, contribute to neoplastic transformation, metastasis, and drug resistance in melanoma...
October 2, 2023: Melanoma Research
Linghui Liang, Jinwei Shang, Yuwei Zhang, Yuxin Xu, Yihui Zhouteng, Jianxiang Wen, Yuxin Zhao, Ninghan Feng, Ruizhe Zhao
BACKGROUND: The role of obesity related genes (ORGs) in the immune checkpoint inhibitors (ICIs) treatment of prostate adenocarcinoma (PRAD) has not yet been proved by research. METHODS: We comprehensively evaluated the ORGs patterns in PRAD based on tumor microenvironment (TME) phenotypes and immunotherapy efficacies. Then we constructed a ORGs risk score for prognosis and a ORGs signature for accurate prediction of TME phenotype and immunotherapy efficacy in order to evaluate individual patients...
October 2, 2023: Aging
Mu Pang, Xizhe Sun, Ting He, Huichao Liang, Hao Yang, Jun Chen
Hepatocellular Carcinoma (HCC) is the predominant cause of cancer-related mortality worldwide. The majority of HCC patients are diagnosed at advanced stages of the disease, with a high likelihood of metastasis and unfavorable prognosis. Anoikis resistance is a crucial factor contributing to tumor invasion and metastasis, although its specific role in HCC remains unclear. Based on the results of univariate Cox regression and least absolute shrink-age and selection operator (LASSO) analysis, a subset of anoikis-related genes (ARGs) significantly associated with overall survival (OS) was identified...
October 2, 2023: Aging
Tianjiao Chu, Bowei Cao, Peina Wang, Bozhao Li, Jinna Ren, Guangjun Nie, Jingyan Wei, Suping Li
As a pleiotropic cytokine, interleukin-2 (IL-2) can effectively regulate lymphocyte proliferation, survival, and active antitumor immune responses in tumor microenvironments. Although the ability of IL-2 to boost immune responses was reported in cancer patients, its short circulating half-life and high toxicity hinder its broad and continual clinical application. Herein, we developed a novel tumor target agent by fusing pH low insertion peptides (pHLIP) with IL-2, forming the fusion protein pHLIP-IL2. Based on the low pH insertion property of pHLIP, the pHLIP-IL2 fusion protein could be selectively delivered to the acidic tumor microenvironments and then promote the proliferation of killer immune cells to elicit tumor regression...
October 3, 2023: Bioconjugate Chemistry
Safaa Altves, Ebru Guclu, Ilknur Cinar Ayan, Kivanc Bilecen, Hasibe Vural
Neuroblastoma is the most common brain solid tumor in infancy. Despite the availability of numerous approaches like immunotherapy, surgery, chemotherapy, and radiotherapy, neuroblastoma frequently develops resistance and recurs. Immunotherapy is one of the most promising approaches and PD-L1 antibody blocking is the phenomena used to inhibit PD-1 receptors to increase and improve cytotoxic T cells toward cancer. Numerous studies underlined the critical role of probiotics on immune system development and modulation in addition to possible role in inducing apoptosis in cancer cells...
October 3, 2023: Medical Oncology
Jiashuo Chao, Shanshan Wang, Hao Wang, Nan Zhang, Yunchao Wang, Xu Yang, Chengpei Zhu, Cong Ning, Xinmu Zhang, Jingnan Xue, Longhao Zhang, Mingjian Piao, Mingming Wang, Xiaobo Yang, Ling Lu, Haitao Zhao
BACKGROUND: In clinical practice, some patients with advanced intrahepatic cholangiocarcinoma (ICC) cannot tolerate or refuse chemotherapy due to the toxicity, necessitating alternative treatments. PD-1 blockade combined with lenvatinib showed promising results in phase II studies with small sample size, but there is a lack of data on the routine use with this regimen. This study aimed to evaluate the effectiveness and safety of the regimen in patients with advanced ICC, and to identify predictors for treatment response and prognosis...
October 3, 2023: Cancer Immunology, Immunotherapy: CII
Alexandre Gouzy
The interaction between Mycobacterium tuberculosis , the agent of tuberculosis (TB), and its host cell, the macrophage, is multifaceted, dynamic, and involves multiple molecular partners. A better understanding of this interaction could help researchers manipulate the immune system in order to design host-targeted immunotherapies and/or develop a novel vaccine protecting better adults against TB. Jani and coworkers studied the role of the macrophage receptor TLR2 in the response to M. tuberculosis using single-cell technologies (C...
October 3, 2023: MSystems
Parag Roy, K M Parthasarathy
The overall prognosis of hepatocellular carcinoma (HCC) is dismal and 5-year survival rate is 14.8%. We report a case of HCC coinfected with hepatitis C virus (HCV) and tumor thrombosis in the portal vein that was initially started on sorafenib followed by lenvatinib and nivolumab. On radiological imaging, there was a good partial response (PR) after starting nivolumab. A female 56 years of age presented with HCC coinfection with HCV, tumor thrombosis growing to the right portal vein. She received 6 months of sorafenib starting from April 2019 and was then switched to lenvatinib due to progressive disease...
2023: Journal of Cancer Research and Therapeutics
Milton José de Barros E Silva, Marcos Rezende Teixeira, Matheus de Melo Lobo, André Sapata Molina, Eduardo Bertolli, Ivan Dunshee de Abranches Oliveira Santos Filho, Heber Salvador Castro Ribeiro, Antônio Cássio de Assis Pelizon, Clóvis Antônio Lopes Pinto, João Pedreira Duprat Neto
BACKGROUND AND OBJECTIVES: New scenarios for local therapy have arisen after starting immune checkpoint inhibitors (ICIs) to treat advanced melanoma (AM). The aim of this study is to examine the role of local therapies with curative intention for patients with AM that have been on ICI. METHODS: This was a single institution, retrospective analysis of unresectable stage III or IV melanoma patients on treatment with anti-PD1 ± anti-CTLA-4 who underwent local therapy with curative intention with no other remaining sites of disease (NRD)...
2023: Journal of Cancer Research and Therapeutics
Rishu Singla, Ankush Jajodia, R K Agrawal, Avinash Rao, Sunil Pasricha, Ullas Batra
BACKGROUND: Systemic therapy in lung cancer is mainstay of treatment as most patients present in advanced stages, with rising importance of new immunotherapy agents. PURPOSE: To compare the RECIST 1.1 and the immunotherapy Response Evaluation Criteria in Solid Tumors (iRECISTs) criteria for response assessment in lung cancer patients on immunotherapy. To find the incidence of pseudoprogression and associated imaging patterns. MATERIAL AND METHODS: Retrospective study in 28 patients treated with immunotherapy for advanced metastatic NSCLC...
2023: Journal of Cancer Research and Therapeutics
Kristina Zakurdaeva, Ilya Tsimafeyeu
Disease management in challenging patient population with cancer and concomitant serious conditions presents an unmet clinical need. The major gap is the lack of data from properly designed trials that could support clinical decisions. Despite many advances in the fields of oncology, immunology, and infectious diseases, chronic viral infections in cancer patients remain to some extent terra incognita. Therefore, many patients lose the opportunity to receive the most advanced therapy, and physicians are compelled to make treatment decisions without sufficient evidence...
2023: Journal of Cancer Research and Therapeutics
Akriti Jindal, Gargi Kapatia, Gaurav Gupta
The most common cause of intraocular mass is metastasis from other tumors. Renal malignancies, though rare, have a substantial number of cases with ocular metastasis, few of which were misdiagnosed. Many a times renal malignancies present with ocular manifestations before the primary diagnosis. Here in this article, we comprehensively reviewed 106 cases of ocular metastasis from renal malignancies published till date to the best of our knowledge. The eye is a rare site for distant metastasis because of the lack of a lymphatic system...
October 2023: Indian Journal of Ophthalmology
Elizabeth Herrity, Mariana Pinto Pereira, Dennis Dong Hwan Kim
Emerging biological and clinical data, along with advances in new technologies, have exposed the mechanistic diversity in post-haematopoietic stem cell transplant (HCT) relapse. Post-HCT relapse mechanisms are relevant for guiding sophisticated selection of therapeutic interventions and identification of areas for further research. Clonal evolution and emergence of resistant leukemic strains is a common mechanism shared by relapse post-chemotherapy and post-HCT, other mechanisms such as leukemic immune escape and donor T cell exhaustion are unique entities to post-HCT relapse...
October 3, 2023: British Journal of Haematology
Mingyu Wan, Yongfeng Ding, Xiaolu Ma, Xiaoyu Chen, Xin Xu, Chenyu Mao, Jiong Qian, Cheng Xiao, Haiping Jiang, Yulong Zheng, Lisong Teng, Nong Xu
BACKGROUND: Notwithstanding that the past decade has witnessed unprecedented medical progress, gastric cancer (GC) remains a leading cause of cancer death, highlighting the need for effective prognostic markers. The Memorial Sloan Kettering Prognostic Score (MPS) has been validated as a valuable prognostic tool for patients with metastatic pancreatic adenocarcinoma (mPDAC). This study aimed to assess the prognostic value of the MPS in advanced GC. METHODS: Data from 367 patients were analyzed in the present study...
October 3, 2023: Cancer Medicine
Alexander Domnich, Daniela Amicizia, Piero Luigi Lai, Matilde Ogliastro, Maria Piedrahita-Tovar, Andrea Orsi, Giancarlo Icardi, Donatella Panatto
The objective of this paper is to summarize annual enhanced safety surveillance activity across three seasons (2019/20-2021/22) for cell culture-based quadrivalent influenza vaccine (QIVc; Flucelvax® Tetra) in all age groups. This activity was conducted in primary care setting in Genoa (Italy) during the seasons 2019/20, 2020/21 and 2021/22. All adverse events registered within the first seven days following immunization were analyzed by season, type, age group and seriousness. Over three seasons, 3,603 QIVc exposures were recorded within the enhanced passive safety surveillance activity...
August 2023: Human Vaccines & Immunotherapeutics
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.